Bicycle Therapeutics

BCYC Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-17

Catalyst timeline

Bicycle Therapeutics corporate update2026Bicycle Therapeutics corporate update, 2026, routine
Zelenectide pevedotin Ph2 readout4Q 2026Zelenectide pevedotin Ph2 readout, 4Q 2026, major
Bicycle Therapeutics corporate updateOct–Nov 2026Bicycle Therapeutics corporate update, Oct–Nov 2026, routine
BT1702 trial start2027BT1702 trial start, 2027, routine
Nuzefatide pevedotin Ph2 interim2H 2027Nuzefatide pevedotin Ph2 interim, 2H 2027, material
ION826/AZD4063 Ph1 readoutNov 22, 2027ION826/AZD4063 Ph1 readout, Nov 22, 2027, notable
EphA2 radioconjugate trial start2028EphA2 radioconjugate trial start, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

nuzefatide pevedotin

BT5528

Peptide Target: EphA2

Pancreatic Ductal Adenocarcinoma Phase 2 Phase I/II trial NCT07450859
Urothelial Cancer Phase 1 Phase I/II trial NCT04180371

zelenectide pevedotin

zelenectide · BT8009

Peptide Target: Nectin-4, NECTIN4

Urothelial Cancer Phase 2 Phase II trial NCT04561362

BT1702

Radioligand Target: MT1-MMP

Undisclosed indication Preclinical

Technology platforms

BRC

Bicycle Radioconjugate platform — fully synthetic bicyclic peptide-based radioconjugates for targeted radionuclide therapy and radiopharmaceutical imaging; focus areas include EphA2 and MT1-MMP as cancer targets; radioisotopes include 177Lu, 68Ga, and 212Pb

Targets: EphA2, MT1-MMP

BRC · SpectronRx

Bicycle Radioconjugates — bicyclic peptide-based radioconjugates for targeted radionuclide therapy and radiopharmaceutical imaging; isotope-agnostic strategy including 212Pb supply chain; focus on oncology targets including EphA2 and MT1-MMP

Targets: EphA2, MT1-MMP

Bicycle

Proprietary bicyclic peptide technology — fully synthetic short peptides constrained with small molecule scaffolds to form two loops, enabling high-affinity and selective target binding; used to develop Bicycle Drug Conjugates (BDC), Bicycle Radioconjugates (BRC), and Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICA) across oncology and additional therapeutic areas

Targets: EphA2, Nectin-4, CD137

Discontinued (3)

zelenectide pevedotin — Breast Cancer · strategic deprioritization; Duravelo-3 trial to be discontinued
zelenectide pevedotin — Non-Small Cell Lung Cancer · strategic deprioritization; Duravelo-4 trial to be discontinued
BT7480 — undisclosed · strategic deprioritization; will no longer develop BT7480 internally, seeking external partner

Biotech Distilled coverage (1)

2026-10-05 Bicycle Therapeutics (BCYC) - Scientific Deep Dive for Nuzefatide Pevedotin, Zelenectide Pevedotin and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.